Author:
Castillo Paul,Ogando-Rivas Elizabeth,Geffrard Hilary,Pepe Alfonso,Liu Ruixuan,Nguyen Duy T,Pedro Diego I,Zhang Dingpeng,DeVries Anna,Qdaisat Sadeem,Karachi Aida,Rahman Maryam,Weidert Frances,Milner Rowan,Huang Jianping,Silver Natalie L.,Ligon John,Li Derek,Lee Ji-Hyun,Carrera-Justiz Sheila,Mitchell Duane A,Mendez-Gomez Hector,Sawyer W Gregory,Sayour Elias J
Abstract
AbstractTo prospectively determine whether brain tumors will respond to immune checkpoint inhibitors (ICIs), we developed a novel mRNA vaccine as a viral mimic to elucidate cytokine release from brain cancer cells in vitro. Our results indicate that cytokine signatures following mRNA challenge differ substantially from ICI responsive versus non-responsive murine tumors. These findings allow for creation of a diagnostic assay to quickly assess brain tumor immunogenicity, allowing for informed treatment with ICI or lack thereof in poorly immunogenic settings.
Publisher
Cold Spring Harbor Laboratory